3/27
08:06 am
pgen
Discover Precigen And 2 Other Insider-Favored Growth Stocks [Yahoo! Finance]
Neutral
Report
Discover Precigen And 2 Other Insider-Favored Growth Stocks [Yahoo! Finance]
3/27
01:18 am
pgen
Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? [Yahoo! Finance]
3/26
09:43 am
pgen
Precigen (PGEN) had its price target raised by Citizens Jmp from $8.00 to $9.00. They now have a "market outperform" rating on the stock.
Low
Report
Precigen (PGEN) had its price target raised by Citizens Jmp from $8.00 to $9.00. They now have a "market outperform" rating on the stock.
3/26
09:12 am
pgen
Precigen gains after 2025 results on Papzimeos outlook [Seeking Alpha]
Low
Report
Precigen gains after 2025 results on Papzimeos outlook [Seeking Alpha]
3/26
08:42 am
pgen
Precigen (PGEN) had its price target raised by HC Wainwright from $9.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Precigen (PGEN) had its price target raised by HC Wainwright from $9.00 to $10.00. They now have a "buy" rating on the stock.
3/25
11:23 pm
pgen
Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... [Yahoo! Finance]
Low
Report
Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... [Yahoo! Finance]
3/25
07:18 pm
pgen
Precigen Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Precigen Q4 Earnings Call Highlights [Yahoo! Finance]
3/25
07:18 pm
pgen
PMI Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
PMI Q4 Earnings Call Highlights [Yahoo! Finance]
3/25
05:48 pm
pgen
Precigen (PGEN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Precigen (PGEN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/25
04:42 pm
pgen
Precigen Reports Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
High
Report
Precigen Reports Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
3/25
04:10 pm
pgen
Precigen Non-GAAP EPS of -$1.37, revenue of $9.7M misses by $3.83M [Seeking Alpha]
Medium
Report
Precigen Non-GAAP EPS of -$1.37, revenue of $9.7M misses by $3.83M [Seeking Alpha]
3/25
04:05 pm
pgen
Precigen Reports Full Year 2025 Financial Results and Business Updates
High
Report
Precigen Reports Full Year 2025 Financial Results and Business Updates
3/19
08:19 am
pgen
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships [Yahoo! Finance]
Low
Report
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships [Yahoo! Finance]
3/12
05:23 pm
pgen
Assessing Precigen (PGEN) Valuation After Recent Share Price Weakness And Conflicting Fair Value Estimates [Yahoo! Finance]
Medium
Report
Assessing Precigen (PGEN) Valuation After Recent Share Price Weakness And Conflicting Fair Value Estimates [Yahoo! Finance]
3/12
06:32 am
pgen
Precigen (PGEN) was upgraded by Zacks Research from "strong sell" to "hold".
Medium
Report
Precigen (PGEN) was upgraded by Zacks Research from "strong sell" to "hold".
3/11
04:05 pm
pgen
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Medium
Report
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
3/5
08:48 am
pgen
Precigen (PGEN) Surged Following the Early Approval of Papziemos [Yahoo! Finance]
Medium
Report
Precigen (PGEN) Surged Following the Early Approval of Papziemos [Yahoo! Finance]
2/11
09:40 am
pgen
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
Medium
Report
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
1/24
06:29 am
pgen
Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/20
08:05 am
pgen
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Low
Report
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
1/12
08:00 am
pgen
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
1/5
05:02 pm
pgen
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
High
Report
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
04:05 pm
pgen
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference